Fulgent Genetics Inc Asset Resilience Ratio
Fulgent Genetics Inc asset resilience ratio. Fulgent Genetics Inc (FLGT) has an Asset Resilience Ratio of 21.18% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See FLGT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Fulgent Genetics Inc (2016–2025)
Asset resilience ratio of Fulgent Genetics Inc from 2016 to 2025. This chart shows how Fulgent Genetics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Fulgent Genetics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Fulgent Genetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Fulgent Genetics Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $230.73 Million | 21.18% |
| Total Liquid Assets | $230.73 Million | 21.18% |
Asset Resilience Insights
- Good Liquidity Position: Fulgent Genetics Inc maintains a healthy 21.18% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Fulgent Genetics Inc Industry Peers by Asset Resilience Ratio
Compare Fulgent Genetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Avricore Health Inc
V:AVCR |
Diagnostics & Research | 1.71% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
Fulgent Genetics Inc Asset Resilience Ratio by Year (2016–2025)
Fulgent Genetics Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Fulgent Genetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 23.56% | $285.88 Million | $1.21 Billion | +6.92pp |
| 2024-12-31 | 16.64% | $202.96 Million | $1.22 Billion | -9.81pp |
| 2023-12-31 | 26.44% | $326.68 Million | $1.24 Billion | -5.79pp |
| 2022-12-31 | 32.23% | $446.73 Million | $1.39 Billion | +9.90pp |
| 2021-12-31 | 22.34% | $285.61 Million | $1.28 Billion | -7.92pp |
| 2020-12-31 | 30.26% | $211.94 Million | $700.46 Million | +11.89pp |
| 2019-12-31 | 18.37% | $16.30 Million | $88.76 Million | -37.40pp |
| 2018-12-31 | 55.77% | $30.68 Million | $55.02 Million | -5.47pp |
| 2017-12-31 | 61.24% | $34.88 Million | $56.95 Million | -5.21pp |
| 2016-12-31 | 66.45% | $38.57 Million | $58.04 Million | -- |
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more